Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

David Raben

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-Radiation Oncology
Phone720/848-0143

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Fakhry C, Zhang Q, Nguyen-Tân PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM, Barrett WL, Thorstad WL, Jones CU, Yom SS, Wong SJ, Ridge JA, Rao SSD, Bonner JA, Vigneault E, Raben D, Kudrimoti MR, Harris J, Le QT, Gillison ML. Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. J Clin Oncol. 2017 Aug 04; JCO2016720748. PMID: 28777690.
      View in: PubMed
    2. Stokes WA, Kavanagh BD, Raben D, Pugh TJ. Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis. Pract Radiat Oncol. 2017 Jul - Aug; 7(4):270-278. PMID: 28673554.
      View in: PubMed
    3. Cicchini L, Blumhagen RZ, Westrich JA, Myers ME, Warren CJ, Siska C, Raben D, Kechris KJ, Pyeon D. High-Risk Human Papillomavirus E7 Alters Host DNA Methylome and Represses HLA-E Expression in Human Keratinocytes. Sci Rep. 2017 Jun 16; 7(1):3633. PMID: 28623356.
      View in: PubMed
    4. Stokes WA, Abbott D, Phan A, Raben D, Lanning RM, Karam SD. Patterns of Care for Patients With Early-Stage Glottic Cancer Undergoing Definitive Radiation Therapy: A National Cancer Database Analysis. Int J Radiat Oncol Biol Phys. 2017 Aug 01; 98(5):1014-1021. PMID: 28721883.
      View in: PubMed
    5. Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017 Apr 01; 3(4):483-491. PMID: 28006059.
      View in: PubMed
    6. Stokes WA, Amini A, Jones BL, McDermott JD, Raben D, Ghosh D, Goddard JA, Bowles DW, Karam SD. Survival impact of induction chemotherapy in advanced head and neck cancer: A National Cancer Database analysis. Head Neck. 2017 Jun; 39(6):1113-1121. PMID: 28301079.
      View in: PubMed
    7. Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ. Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. Urol Oncol. 2017 Jun; 35(6):438-446. PMID: 28214281.
      View in: PubMed
    8. Bhatia S, Hirsch K, Sharma J, Oweida A, Griego A, Keysar S, Jimeno A, Raben D, Krasnoperov V, Gill PS, Pasquale EB, Wang XJ, Karam SD. Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas. Sci Rep. 2016 Dec 12; 6:38792. PMID: 27941840.
      View in: PubMed
    9. Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr 01; 123(7):1259-1271. PMID: 27906454.
      View in: PubMed
    10. Tu-Sekine B, Raben DM. Measuring Diacylglycerol Kinase-? Activity and Binding. Methods Enzymol. 2017; 583:231-253. PMID: 28063493.
      View in: PubMed
    11. Amini A, Waxweiler TV, Brower JV, Jones BL, McDermott JD, Raben D, Ghosh D, Bowles DW, Karam SD. Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients With Resected Major Salivary Gland Carcinoma: Data From the National Cancer Data Base. JAMA Otolaryngol Head Neck Surg. 2016 Nov 01; 142(11):1100-1110. PMID: 27541166.
      View in: PubMed
    12. Stokes WA, Jones BL, Bhatia S, Oweida AJ, Bowles DW, Raben D, Goddard JA, McDermott JD, Karam SD. A comparison of overall survival for patients with T4 larynx cancer treated with surgical versus organ-preservation approaches: A National Cancer Data Base analysis. Cancer. 2017 Feb 15; 123(4):600-608. PMID: 27727461.
      View in: PubMed
    13. Xiao C, Zhang Q, Nguyen-Tân PF, List M, Weber RS, Ang KK, Rosenthal D, Filion EJ, Kim H, Silverman C, Raben A, Galloway T, Fortin A, Gore E, Winquist E, Jones CU, Robinson W, Raben D, Le QT, Bruner D. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129. Int J Radiat Oncol Biol Phys. 2017 Mar 15; 97(4):667-677. PMID: 27727063.
      View in: PubMed
    14. Divi V, Harris J, Harari PM, Cooper JS, McHugh J, Bell D, Sturgis EM, Cmelak AJ, Suntharalingam M, Raben D, Kim H, Spencer SA, Laramore GE, Trotti A, Foote RL, Schultz C, Thorstad WL, Zhang QE, Le QT, Holsinger FC. Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer. 2016 Jul 15. PMID: 27419843.
      View in: PubMed
    15. Kim DN, Straka C, Cho LC, Lotan Y, Yan J, Kavanagh B, Raben D, Cooley S, Brindle J, Xie XJ, Pistenmaa D, Timmerman R. Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial. Pract Radiat Oncol. 2017 Jan - Feb; 7(1):e43-e49. PMID: 27637137.
      View in: PubMed
    16. Bonner JA, Giralt J, Harari PM, Baselga J, Spencer S, Bell D, Raben D, Liu J, Schulten J, Ang KK, Rosenthal DI. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial. Eur J Cancer. 2016 Sep; 64:1-11. PMID: 27323346.
      View in: PubMed
    17. Bowles DW, Deutsch E, Raben D. Successes and Failures of Combined Modality Therapies in Head and Neck Cancer. Semin Radiat Oncol. 2016 Oct; 26(4):299-306. PMID: 27619251.
      View in: PubMed
    18. Hannan R, Tumati V, Xie XJ, Cho LC, Kavanagh BD, Brindle J, Raben D, Nanda A, Cooley S, Kim DW, Pistenmaa D, Lotan Y, Timmerman R. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Eur J Cancer. 2016 May; 59:142-51. PMID: 27035363.
      View in: PubMed
    19. Bar-Ad V, Zhang QE, Harari PM, Axelrod R, Rosenthal DI, Trotti A, Jones CU, Garden AS, Song G, Foote RL, Raben D, Shenouda G, Spencer SA, Harris J, Le QT. Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience. Int J Radiat Oncol Biol Phys. 2016 Aug 01; 95(5):1346-54. PMID: 27212198.
      View in: PubMed
    20. Amini A, Jasem J, Jones BL, Robin TP, McDermott JD, Bhatia S, Raben D, Jimeno A, Bowles DW, Karam SD. Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base. Oral Oncol. 2016 May; 56:1-7. PMID: 27086480.
      View in: PubMed
    21. Amini A, Jones BL, McDermott JD, Serracino HS, Jimeno A, Raben D, Ghosh D, Bowles DW, Karam SD. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base. Cancer. 2016 05 15; 122(10):1533-43. PMID: 26969811.
      View in: PubMed
    22. O'Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, Lee N, Riaz N, Pei X, Koyfman SA, Adelstein D, Burkey BB, Friborg J, Kristensen CA, Gothelf AB, Hoebers F, Kremer B, Speel EJ, Bowles DW, Raben D, Karam SD, Yu E, Xu W. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016 Apr; 17(4):440-51. PMID: 26936027.
      View in: PubMed
    23. Amini A, Jones BL, Jackson MW, Rusthoven CG, Maroni P, Kavanagh BD, Raben D. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base. Brachytherapy. 2016 Mar-Apr; 15(2):136-46. PMID: 26825856.
      View in: PubMed
    24. Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, Schulten J, Ang KK, Bonner JA. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. J Clin Oncol. 2016 Apr 20; 34(12):1300-8. PMID: 26712222.
      View in: PubMed
    25. Gan GN, Altunbas C, Morton JJ, Eagles J, Backus J, Dzingle W, Raben D, Jimeno A. Radiation dose uncertainty and correction for a mouse orthotopic and xenograft irradiation model. Int J Radiat Biol. 2016; 92(1):50-6. PMID: 26689828; PMCID: PMC4750646 [Available on 01/01/17].
    26. Amini A, Rusthoven CG, Jones BL, Armstrong H, Raben D, Kavanagh BD. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base. Urol Oncol. 2016 Apr; 34(4):165.e1-9. PMID: 26699831.
      View in: PubMed
    27. Amini A, Rusthoven CG, Waxweiler TV, Jones BL, Fisher CM, Karam SD, Raben D. Association of health insurance with outcomes in adults ages 18 to 64 years with melanoma in the United States. J Am Acad Dermatol. 2016 Feb; 74(2):309-16. PMID: 26670715.
      View in: PubMed
    28. Amini A, Jones B, Jackson MW, Yeh N, Waxweiler TV, Maroni P, Kavanagh BD, Raben D. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base. J Urol. 2016 May; 195(5):1453-8. PMID: 26576709.
      View in: PubMed
    29. Stickel SA, Gomes NP, Frederick B, Raben D, Su TT. Bouvardin is a Radiation Modulator with a Novel Mechanism of Action. Radiat Res. 2015 Oct; 184(4):392-403. PMID: 26414509; PMCID: PMC4643058 [Available on 10/01/16].
    30. Robin TP, Gan GN, Tam M, Westerly D, Riaz N, Karam SD, Lee N, Raben D. Safety of contralateral submandibular gland sparing in locally advanced oropharyngeal cancers: A multicenter review. Head Neck. 2016 Apr; 38(4):506-11. PMID: 25482748.
      View in: PubMed
    31. Papadimitrakopoulou VA, Frank SJ, Cohen EW, Hirsch FR, Myers JN, Heymach JV, Lin H, Tran HT, Chen CR, Jimeno A, Nedzi L, Vasselli JR, Lowe ES, Raben D. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck. 2016 Mar; 38(3):439-47. PMID: 25352401; PMCID: PMC4414661.
    32. Kessler ER, Amini A, Wilson SS, Breaker K, Raben D, La Rosa FG. Lymphoepithelioma-Like Carcinoma of the Urinary Bladder. Oncology (Williston Park). 2015 Jun; 29(6):462, C3. PMID: 26089221.
      View in: PubMed
    33. Dan TD, Raben D, Schneider CJ, Hockstein NG, Witt RL, Dzeda M, Cormier JF, Raben A. Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-positive tonsil cancer: updated results of an institutional clinical management approach. Oral Oncol. 2015 Jun; 51(6):616-21. PMID: 25868716.
      View in: PubMed
    34. Amini A, Westerly DC, Waxweiler TV, Ryan N, Raben D. Dose painting to treat single-lobe prostate cancer with hypofractionated high-dose radiation using targeted external beam radiation: Is it feasible? Med Dosim. 2015; 40(3):256-61. PMID: 25824420.
      View in: PubMed
    35. Wozniak AJ, Moon J, Thomas CR, Kelly K, Mack PC, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ, Gandara DR. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer. 2015 Sep; 16(5):340-7. PMID: 25703100; PMCID: PMC4497941.
    36. Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 01; 21(7):1566-73. PMID: 25573383.
      View in: PubMed
    37. Yom SS, Diehn M, Raben D. Molecular determinants of radiation response in non-small cell lung cancer. Semin Radiat Oncol. 2015 Apr; 25(2):67-77. PMID: 25771410.
      View in: PubMed
    38. Amini A, McDermott JD, Gan G, Bhatia S, Sumner W, Fisher CM, Jimeno A, Bowles DW, Raben D, Karam SD. Stereotactic body radiotherapy as primary therapy for head and neck cancer in the elderly or patients with poor performance. Front Oncol. 2014; 4:274. PMID: 25340041; PMCID: PMC4189612.
    39. Gan GN, Eagles J, Keysar SB, Wang G, Glogowska MJ, Altunbas C, Anderson RT, Le PN, Morton JJ, Frederick B, Raben D, Wang XJ, Jimeno A. Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers. Cancer Res. 2014 Dec 01; 74(23):7024-36. PMID: 25297633; PMCID: PMC4253591.
    40. Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, Jordan RC, Le QT. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol. 2014 Dec 10; 32(35):3930-8. PMID: 25267748; PMCID: PMC4251957.
    41. Rusthoven CG, Waxweiler TV, DeWitt PE, Flaig TW, Raben D, Kavanagh BD. Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer. Urol Oncol. 2015 Feb; 33(2):71.e11-9. PMID: 25151595.
      View in: PubMed
    42. Kim DW, Cho LC, Straka C, Christie A, Lotan Y, Pistenmaa D, Kavanagh BD, Nanda A, Kueplian P, Brindle J, Cooley S, Perkins A, Raben D, Xie XJ, Timmerman RD. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014 Jul 01; 89(3):509-17. PMID: 24929162.
      View in: PubMed
    43. Rusthoven CG, Carlson JA, Waxweiler TV, Raben D, Dewitt PE, Crawford ED, Maroni PD, Kavanagh BD. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1064-73. PMID: 24661660.
      View in: PubMed
    44. Rusthoven CG, Carlson JA, Waxweiler TV, Yeh N, Raben D, Flaig TW, Kavanagh BD. The prognostic significance of Gleason scores in metastatic prostate cancer. Urol Oncol. 2014 Jul; 32(5):707-13. PMID: 24629494.
      View in: PubMed
    45. Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, Paylor JJ, Glogowska MJ, Le PN, Eagles-Soukup JR, Kako SL, Takimoto SM, Sehrt DB, Umpierrez A, Pittman MA, Macfadden SM, Helber RM, Peterson S, Hausman DF, Said S, Leem TH, Goddard JA, Arcaroli JJ, Messersmith WA, Robinson WA, Hirsch FR, Varella-Garcia M, Raben D, Wang XJ, Song JI, Tan AC, Jimeno A. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol. 2013 Aug; 7(4):776-90. PMID: 23607916; PMCID: PMC3760013.
    46. Han G, Bian L, Li F, Cotrim A, Wang D, Lu J, Deng Y, Bird G, Sowers A, Mitchell JB, Gutkind JS, Zhao R, Raben D, ten Dijke P, Refaeli Y, Zhang Q, Wang XJ. Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. Nat Med. 2013 Apr; 19(4):421-8. PMID: 23475202; PMCID: PMC3780964.
    47. Carlson J, Licitra L, Locati L, Raben D, Persson F, Stenman G. Salivary gland cancer: an update on present and emerging therapies. Am Soc Clin Oncol Educ Book. 2013; 257-63. PMID: 23714518.
      View in: PubMed
    48. Raben D, Bunn PA. Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III non-small-cell lung cancer: a case of the Icarus syndrome? J Clin Oncol. 2012 Nov 10; 30(32):3909-12. PMID: 23045597.
      View in: PubMed
    49. Amin N, Reddy K, Westerly D, Raben D, DeWitt P, Chen C. Sparing the larynx and esophageal inlet expedites feeding tube removal in patients with stage III-IV oropharyngeal squamous cell carcinoma treated with intensity-modulated radiotherapy. Laryngoscope. 2012 Dec; 122(12):2736-42. PMID: 22991101.
      View in: PubMed
    50. Oberley-Deegan RE, Steffan JJ, Rove KO, Pate KM, Weaver MW, Spasojevic I, Frederick B, Raben D, Meacham RB, Crapo JD, Koul HK. The antioxidant, MnTE-2-PyP, prevents side-effects incurred by prostate cancer irradiation. PLoS One. 2012; 7(9):e44178. PMID: 22984473; PMCID: PMC3440381.
    51. Kilbourn KM, Anderson D, Costenaro A, Lusczakoski K, Borrayo E, Raben D. Feasibility of EASE: a psychosocial program to improve symptom management in head and neck cancer patients. Support Care Cancer. 2013 Jan; 21(1):191-200. PMID: 22699303.
      View in: PubMed
    52. Gladstone M, Frederick B, Zheng D, Edwards A, Yoon P, Stickel S, DeLaney T, Chan DC, Raben D, Su TT. A translation inhibitor identified in a Drosophila screen enhances the effect of ionizing radiation and taxol in mammalian models of cancer. Dis Model Mech. 2012 May; 5(3):342-50. PMID: 22344740; PMCID: PMC3339828.
    53. Bowles DW, Reddy K, Wine T, Ree A, Raben D, Chen C, Jimeno A. Locoregional recurrence of an HPV-positive squamous cell carcinoma of the head and neck. Oncology (Williston Park). 2011 Oct; 25(11):1042-8. PMID: 22106555.
      View in: PubMed
    54. Amin NP, Miften M, Kavanagh B, Raben D, Camidge DR, Thornton D, Rochford N, Gaspar LE. Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer. J Thorac Oncol. 2011 Sep; 6(9):1553-62. PMID: 21642862.
      View in: PubMed
    55. Siddiqui F, Raben D, Lu JJ, Grecula JC, Lo SS, Huang Z, Mayr NA, Teh BS, Yao M. Emerging applications of stereotactic body radiation therapy for head and neck cancer. Expert Rev Anticancer Ther. 2011 Sep; 11(9):1429-36. PMID: 21929316.
      View in: PubMed
    56. Gregoire V, Hamoir M, Chen C, Kane M, Kawecki A, Julka PK, Wang HM, Prasad S, D'Cruz AK, Radosevic-Jelic L, Kumar RR, Korzeniowski S, Fijuth J, Machiels JP, Sellers MV, Tchakov I, Raben D. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study. Radiother Oncol. 2011 Jul; 100(1):62-9. PMID: 21821303.
      View in: PubMed
    57. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, O'Sullivan B, He Z, Peng Y, Tan AC, Zhou L, Shen J, Han G, Wang XJ, Thorburn J, Thorburn A, Jimeno A, Raben D, Bedford JS, Li CY. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med. 2011 Jul 03; 17(7):860-6. PMID: 21725296; PMCID: PMC3132290.
    58. Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D, Heasley LE. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2011 Aug 01; 17(15):5016-25. PMID: 21673064; PMCID: PMC3149730.
    59. Kavanagh BD, Raben D. Back to the future: a proton pro/con. Oncology (Williston Park). 2011 Jun; 25(7):657, 660, 662-3. PMID: 21888267.
      View in: PubMed
    60. Edwards A, Gladstone M, Yoon P, Raben D, Frederick B, Su TT. Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells. Dis Model Mech. 2011 Jul; 4(4):496-503. PMID: 21504911; PMCID: PMC3124055.
    61. Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M, Raben D. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011 Apr 08; 6:34. PMID: 21477295; PMCID: PMC3094365.
    62. Pugh TJ, Lee NY, Pacheco T, Raben D. Microcystic adnexal carcinoma of the face treated with radiation therapy: a case report and review of the literature. Head Neck. 2012 Jul; 34(7):1045-50. PMID: 21384456.
      View in: PubMed
    63. Chung CH, Raben D. p16 Expression as a predictive biomarker of hypoxic cell-sensitizing agents in oropharyngeal cancer. J Clin Oncol. 2010 Sep 20; 28(27):4103-4. PMID: 20697096.
      View in: PubMed
    64. Diot Q, Olsen C, Kavanagh B, Raben D, Miften M. Dosimetric effect of online image-guided anatomical interventions for postprostatectomy cancer patients. Int J Radiat Oncol Biol Phys. 2011 Feb 01; 79(2):623-32. PMID: 20643519.
      View in: PubMed
    65. Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen C. Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1020-5. PMID: 20231078.
      View in: PubMed
    66. Pugh TJ, Chen C, Rabinovitch R, Eckhardt SG, Rusthoven KE, Swing R, Raben D. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. Int J Radiat Oncol Biol Phys. 2010 Oct 01; 78(2):521-6. PMID: 20133082.
      View in: PubMed
    67. Diot Q, Olsen C, Kavanagh B, Raben D, Miften M. Impact of anatomical interventions on the localization of post-prostatectomy cancer patients. Med Phys. 2010 Feb; 37(2):629-37. PMID: 20229872.
      View in: PubMed
    68. Ammer AG, Kelley LC, Hayes KE, Evans JV, Lopez-Skinner LA, Martin KH, Frederick B, Rothschild BL, Raben D, Elvin P, Green TP, Weed SA. Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function. J Cancer Sci Ther. 2009 Nov 30; 1(2):52-61. PMID: 20505783.
      View in: PubMed
    69. Rusthoven KE, Raben D, Song JI, Kane M, Altoos TA, Chen C. Survival and patterns of relapse in patients with oral tongue cancer. J Oral Maxillofac Surg. 2010 Mar; 68(3):584-9. PMID: 19939533.
      View in: PubMed
    70. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan; 11(1):21-8. PMID: 19897418.
      View in: PubMed
    71. Okunieff P, Kachnic LA, Constine LS, Fuller CD, Gaspar LE, Hayes DF, Hooks J, Ling C, Meyskens FL, Philip PA, Raben D, Smalley SR, Swanson GP, Teicher BA, Thomas CR, Vikram B, Zelefsky MJ, Baker LH. Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008. Clin Cancer Res. 2009 Sep 15; 15(18):5663-70. PMID: 19723641; PMCID: PMC2978526.
    72. Brechbuhl HM, Min E, Kariya C, Frederick B, Raben D, Day BJ. Select cyclopentenone prostaglandins trigger glutathione efflux and the role of ABCG2 transport. Free Radic Biol Med. 2009 Sep 15; 47(6):722-30. PMID: 19520157; PMCID: PMC2730198.
    73. McCammon R, Rusthoven KE, Kavanagh B, Newell S, Newman F, Raben D. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Oct 01; 75(2):413-20. PMID: 19362783.
      View in: PubMed
    74. Olsen CC, Schefter TE, Chen H, Kane M, Leong S, McCarter MD, Chen Y, Mack P, Eckhardt SG, Stiegmann G, Raben D. Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy. Am J Clin Oncol. 2009 Apr; 32(2):115-21. PMID: 19307945.
      View in: PubMed
    75. Raben A, Rusthoven KE, Sarkar A, Glick A, Benge B, Jacobs D, Raben D. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy. Brachytherapy. 2009 Jul-Sep; 8(3):297-303. PMID: 19213608.
      View in: PubMed
    76. Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int. 2009 Jun; 103(12):1729-37. PMID: 19220256.
      View in: PubMed
    77. Rusthoven KE, Raben D, Schneider C, Witt R, Sammons S, Raben A. Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-positive tonsil cancer: results of a prospective management approach. Int J Radiat Oncol Biol Phys. 2009 Aug 01; 74(5):1365-70. PMID: 19168295.
      View in: PubMed
    78. Le QT, Raben D. Integrating biologically targeted therapy in head and neck squamous cell carcinomas. Semin Radiat Oncol. 2009 Jan; 19(1):53-62. PMID: 19028346; PMCID: PMC2634835.
    79. Bradshaw-Pierce EL, Steinhauer CA, Raben D, Gustafson DL. Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma. Mol Cancer Ther. 2008 Sep; 7(9):3006-17. PMID: 18790781; PMCID: PMC2673509.
    80. Ballonoff A, Kavanagh B, McCarter M, Kane M, Pearlman N, Nash R, Shah RJ, Raben D, Schefter TE. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol. 2008 Jun; 31(3):264-70. PMID: 18525306.
      View in: PubMed
    81. Ballonoff A, Raben D, Rusthoven KE, Bassetti M, Kane M, Song JI, Chen C. Outcomes of patients with n3 neck nodes treated with chemoradiation. Laryngoscope. 2008 Jun; 118(6):995-8. PMID: 18364595.
      View in: PubMed
    82. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008 May 17; 371(9625):1695-709. PMID: 18486742.
      View in: PubMed
    83. Rusthoven KE, Raben D, Chen C. Improved survival in patients with Stage III-IV Head and neck cancer treated with radiotherapy as primary local treatment modality. Int J Radiat Oncol Biol Phys. 2008 Oct 01; 72(2):343-50. PMID: 18374508.
      View in: PubMed
    84. Rusthoven KE, Raben D, Ballonoff A, Kane M, Song JI, Chen C. Effect of radiation techniques in treatment of oropharynx cancer. Laryngoscope. 2008 Apr; 118(4):635-9. PMID: 18176348.
      View in: PubMed
    85. Rusthoven KE, Flaig TW, Raben D, Kavanagh BD. High incidence of lung cancer after non-muscle-invasive transitional cell carcinoma of the bladder: implications for screening trials. Clin Lung Cancer. 2008 Mar; 9(2):106-11. PMID: 18501097.
      View in: PubMed
    86. Rusthoven K, Ballonoff A, Raben D, Chen C. Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma. Cancer. 2008 Jan 15; 112(2):345-51. PMID: 18041071.
      View in: PubMed
    87. Rusthoven K, Chen C, Raben D, Kavanagh B. Use of external beam radiotherapy is associated with reduced incidence of second primary head and neck cancer: a SEER database analysis. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):192-8. PMID: 18078720.
      View in: PubMed
    88. Chen C, Kane M, Song J, Campana J, Raben A, Hu K, Harrison L, Quon H, Dancey J, Baron A, Said S, Eckhardt SG, Raben D. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol. 2007 Nov 01; 25(31):4880-6. PMID: 17971583.
      View in: PubMed
    89. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA, Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther. 2007 Jun; 6(6):1683-91. PMID: 17541031.
      View in: PubMed
    90. Gustafson DL, Frederick B, Merz AL, Raben D. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol. 2008 Feb; 61(2):179-88. PMID: 17393165.
      View in: PubMed
    91. Willey CD, Murphy BA, Netterville JL, Burkey BB, Shyr Y, Shakhtour B, Kish B, Raben D, Chen C, Song JI, Kane MA, Cmelak AJ. A Phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patients. Int J Radiat Oncol Biol Phys. 2007 Apr 01; 67(5):1323-31. PMID: 17289289.
      View in: PubMed
    92. Harari PM, Cohen RB, Raben D, Myers JN, Vokes EE, Weber RS, Ang KK. The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium. Int J Radiat Oncol Biol Phys. 2007; 69(2 Suppl):S1-3. PMID: 17848271.
      View in: PubMed
    93. Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res. 2006 Dec 01; 12(23):7117-25. PMID: 17145836.
      View in: PubMed
    94. Bianco C, Giovannetti E, Ciardiello F, Mey V, Nannizzi S, Tortora G, Troiani T, Pasqualetti F, Eckhardt G, de Liguoro M, Ricciardi S, Del Tacca M, Raben D, Cionini L, Danesi R. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res. 2006 Dec 01; 12(23):7099-107. PMID: 17145834.
      View in: PubMed
    95. Rothschild BL, Shim AH, Ammer AG, Kelley LC, Irby KB, Head JA, Chen L, Varella-Garcia M, Sacks PG, Frederick B, Raben D, Weed SA. Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. Cancer Res. 2006 Aug 15; 66(16):8017-25. PMID: 16912177.
      View in: PubMed
    96. Kavanagh BD, Raben D. Toward a unified target theory in oncology. Future Oncol. 2006 Aug; 2(4):435-6. PMID: 16922608.
      View in: PubMed
    97. Lewis KD, Dollarhide S, Fitzpatrick JE, Gonzalez R, High WA, McCarter MD, Olsen C, Raben D. Metastatic malignant melanoma from an unknown primary presenting as a large axillary mass. Oncology (Williston Park). 2006 Jun; 20(7):763-70. PMID: 16841798.
      View in: PubMed
    98. Rabinovitch R, Grant B, Berkey BA, Raben D, Ang KK, Fu KK, Cooper JS. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head Neck. 2006 Apr; 28(4):287-96. PMID: 16287132.
      View in: PubMed
    99. Ballonoff A, Chen C, Raben D. Current radiation therapy management issues in oral cavity cancer. Otolaryngol Clin North Am. 2006 Apr; 39(2):365-80. PMID: 16580917.
      View in: PubMed
    100. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 09; 354(6):567-78. PMID: 16467544.
      View in: PubMed
    101. Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD, McCarter MD, Burri S, Nedzi LA, Sawyer TE, Gaspar LE. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006; 45(7):848-55. PMID: 16982549.
      View in: PubMed
    102. Frederick B, Gustafson D, Bianco C, Ciardiello F, Dimery I, Raben D. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Jan 01; 64(1):33-7. PMID: 16377413.
      View in: PubMed
    103. Raben D, Ryan A. Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005? Clin Lung Cancer. 2005 Nov; 7(3):175-9. PMID: 16354311.
      View in: PubMed
    104. Damiano V, Melisi D, Bianco C, Raben D, Caputo R, Fontanini G, Bianco R, Ryan A, Bianco AR, De Placido S, Ciardiello F, Tortora G. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res. 2005 Aug 01; 11(15):5639-44. PMID: 16061883.
      View in: PubMed
    105. Ding M, Newman F, Raben D. New radiation therapy techniques for the treatment of head and neck cancer. Otolaryngol Clin North Am. 2005 Apr; 38(2):371-95, vii-viii. PMID: 15823599.
      View in: PubMed
    106. Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):795-805. PMID: 15701870.
      View in: PubMed
    107. Song J, Chen C, Raben D. Emerging role of EGFR-targeted therapies and radiation in head and neck cancer. Oncology (Williston Park). 2004 Dec; 18(14):1757-67; discussion 1767, 1771-2, 1777. PMID: 15700625.
      View in: PubMed
    108. Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther. 2004 Aug; 3(8):977-83. PMID: 15299080.
      View in: PubMed
    109. Raben D, Helfrich B. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer? Clin Lung Cancer. 2004 Jul; 6(1):48-57. PMID: 15310417.
      View in: PubMed
    110. Raben D, Bianco C, Milas L, Ang KK. Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress? Semin Radiat Oncol. 2004 Apr; 14(2):139-52. PMID: 15095260.
      View in: PubMed
    111. Raben D, Helfrich B, Bunn PA. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys. 2004; 59(2 Suppl):27-38. PMID: 15142632.
      View in: PubMed
    112. Tu-Sekine B, Raben DM. Nuclear production and metabolism of diacylglycerol. Eur J Histochem. 2004; 48(1):77-82. PMID: 15145778.
      View in: PubMed
    113. Okunieff P, Meyn RE, Teicher BA, Thomas CR, Gaspar LE, Raben D, Giri S, Lavey RS, Turrisi AT, Swanson GP, Smalley SR. Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2003. Am J Clin Oncol. 2003 Oct; 26(5):522-9. PMID: 14528084.
      View in: PubMed
    114. Raben D, Helfrich B, Ciardiello F, Bunn PA. Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. Lung Cancer. 2003 Aug; 41 Suppl 1:S15-22. PMID: 12867058.
      View in: PubMed
    115. Di Lorenzo G, Autorino R, Ciardiello F, Raben D, Bianco C, Troiani T, Pizza C, De Laurentiis M, Pensabene M, D'Armiento M, Bianco AR, De Placido S. External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life. Oncol Rep. 2003 Mar-Apr; 10(2):399-404. PMID: 12579279.
      View in: PubMed
    116. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, Ciardiello F. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res. 2002 Oct; 8(10):3250-8. PMID: 12374696.
      View in: PubMed
    117. Raben D, Bianco C, Helfrich B, Weng E, Ciardiello F, Harari P. Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment. Expert Rev Anticancer Ther. 2002 Aug; 2(4):461-71. PMID: 12647989.
      View in: PubMed
    118. Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):37-46. PMID: 11894012.
      View in: PubMed
    119. Bregoli L, Baldassare JJ, Raben DM. Nuclear diacylglycerol kinase-theta is activated in response to alpha-thrombin. J Biol Chem. 2001 Jun 29; 276(26):23288-95. PMID: 11309392.
      View in: PubMed
    120. Raben DM, Baldassare JJ. Nuclear envelope signaling-role of phospholipid metabolism. Eur J Histochem. 2000; 44(1):67-80. PMID: 10868295.
      View in: PubMed
    121. Raben DM, Baldassare JJ. Phospholipid metabolism and nuclear envelope signaling. Adv Enzyme Regul. 2000; 40:97-123. PMID: 10828348.
      View in: PubMed
    122. Cheng J, Baldassare JJ, Raben DM. Dual coupling of the alpha-thrombin receptor to signal-transduction pathways involving phosphatidylinositol and phosphatidylcholine metabolism. Biochem J. 1999 Jan 01; 337 ( Pt 1):97-104. PMID: 9854030; PMCID: PMC1219941.
    123. Cheng J, Weber JD, Baldassare JJ, Raben DM. Ablation of Go alpha-subunit results in a transformed phenotype and constitutively active phosphatidylcholine-specific phospholipase C. J Biol Chem. 1997 Jul 11; 272(28):17312-9. PMID: 9211868.
      View in: PubMed
    124. Raben DM, Jarpe MB, Leach KL. Nuclear lipid metabolism in NEST: Nuclear Envelope Signal Transduction. J Membr Biol. 1994 Oct; 142(1):1-7. PMID: 7707346.
      View in: PubMed
    125. Doering TL, Pessin MS, Hart GW, Raben DM, Englund PT. The fatty acids in unremodelled trypanosome glycosyl-phosphatidylinositols. Biochem J. 1994 May 01; 299 ( Pt 3):741-6. PMID: 8192662; PMCID: PMC1138083.
    126. Jarpe MB, Leach KL, Raben DM. Alpha-thrombin-induced nuclear sn-1,2-diacylglycerols are derived from phosphatidylcholine hydrolysis in cultured fibroblasts. Biochemistry. 1994 Jan 18; 33(2):526-34. PMID: 8286382.
      View in: PubMed
    127. Doering TL, Pessin MS, Hoff EF, Hart GW, Raben DM, Englund PT. Trypanosome metabolism of myristate, the fatty acid required for the variant surface glycoprotein membrane anchor. J Biol Chem. 1993 May 05; 268(13):9215-22. PMID: 8486622.
      View in: PubMed
    128. Wright TM, Willenberger S, Raben DM. Activation of phospholipase D by alpha-thrombin or epidermal growth factor contributes to the formation of phosphatidic acid, but not to observed increases in 1,2-diacylglycerol. Biochem J. 1992 Jul 15; 285 ( Pt 2):395-400. PMID: 1637333; PMCID: PMC1132801.
    129. Pessin MS, Altin JG, Jarpe M, Tansley F, Bradshaw RA, Raben DM. Carbachol stimulates a different phospholipid metabolism than nerve growth factor and basic fibroblast growth factor in PC12 cells. Cell Regul. 1991 May; 2(5):383-90. PMID: 1892912; PMCID: PMC361807.
    130. Rangan LA, Wright TM, Raben DM. Differential dependence of early and late increases in 1,2-diacylglycerol on the presence of catalytically active alpha-thrombin: evidence for regulation at the level of 1,2-diacylglycerol generation. Cell Regul. 1991 Apr; 2(4):311-6. PMID: 2059659; PMCID: PMC361783.
    131. Raben DM, Pessin MS, Rangan LA, Wright TM. Kinetic and molecular species analyses of mitogen-induced increases in diglycerides: evidence for stimulated hydrolysis of phosphoinositides and phosphatidylcholine. J Cell Biochem. 1990 Oct; 44(2):117-25. PMID: 2174445.
      View in: PubMed
    132. Pessin MS, Baldassare JJ, Raben DM. Molecular species analysis of mitogen-stimulated 1,2-diglycerides in fibroblasts. Comparison of alpha-thrombin, epidermal growth factor, and platelet-derived growth factor. J Biol Chem. 1990 May 15; 265(14):7959-66. PMID: 2335511.
      View in: PubMed
    133. Wright TM, Shin HS, Raben DM. Sustained increase in 1,2-diacylglycerol precedes DNA synthesis in epidermal-growth-factor-stimulated fibroblasts. Evidence for stimulated phosphatidylcholine hydrolysis. Biochem J. 1990 Apr 15; 267(2):501-7. PMID: 2159287; PMCID: PMC1131317.
    134. Pessin MS, Raben DM. Molecular species analysis of 1,2-diglycerides stimulated by alpha-thrombin in cultured fibroblasts. J Biol Chem. 1989 May 25; 264(15):8729-38. PMID: 2542285.
      View in: PubMed
    135. Wright TM, Rangan LA, Shin HS, Raben DM. Kinetic analysis of 1,2-diacylglycerol mass levels in cultured fibroblasts. Comparison of stimulation by alpha-thrombin and epidermal growth factor. J Biol Chem. 1988 Jul 05; 263(19):9374-80. PMID: 3132463.
      View in: PubMed
    136. Lieberman MA, Rothenberg P, Raben DM, Glaser L. Effect of 3T3 plasma membranes on cells exposed to epidermal growth factor. Biochem Biophys Res Commun. 1980 Jan 29; 92(2):696-702. PMID: 6243947.
      View in: PubMed
    Raben's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)